Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108529 | 1.00 | FFAR1 (0.51) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL3134939 | 0.98 | FFAR1 (0.54) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL3134932 | 0.98 | FFAR1 (0.54) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL10583720 | 0.93 | FFAR1 (0.45) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL10583718 | 0.93 | FFAR1 (0.45) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL449788 | 0.86 | FFAR1 (0.64) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL449789 | 0.86 | FFAR1 (0.64) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL16502016 | 0.84 | — | — | |
| SCHEMBL11193975 | 0.83 | FFAR1 (0.56) | FFAR1FFAR4FAAHGPR84NFKB1 | |
| SCHEMBL26090214 | 0.83 | FFAR1 (0.56) | FFAR1FFAR4FAAHGPR84NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114829004-A | Method for preparing Ni-X-based oxide catalyst and application thereof in transfer hydrogenation | 中国科学院青岛生物能源与过程研究所 | 2022-07-29 | — | — | CN | claimed |
| US-8030010-B2 | Method for detecting a biomarker of oxidative stress in a biological sample | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2011-10-04 | — | — | US | claimed |
| US-20090111121-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2009-04-30 | — | — | US | claimed |
| CN-101379396-A | Method for detecting biomarkers of oxidative stress in biological samples | INST CARDIOLOGIE MONTREAL (CA) | 2009-03-04 | — | — | CN | claimed |
| US-20030153483-A1 | Concentrated, stable fabric softening composition | TRINH TOAN (US) | 2003-08-14 | — | — | US | claimed |
| EP-0842250-A1 | CONCENTRATED, STABLE FABRIC SOFTENING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997003169-A1 | CONCENTRATED, STABLE FABRIC SOFTENING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1997-01-30 | — | — | WO | claimed |
| EP-3510014-B1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NASH OR ALD | METABOLIC TECH INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260102458-A1 | METHODS OF TREATING LONG TERM CORONAVIRUS INFECTION | UNIV MIAMI (US) | 2026-04-16 | — | — | US | disclosed |
| CN-116601159-B | Prodrug of aldehyde ketone reductase inhibitor, pimestat disulfide, preparation, pharmaceutical composition and application thereof | 斯洛伐克科学院实验医学中心 | 2026-02-27 | — | — | CN | disclosed |
| US-20250360094-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | MTI BIOTECH INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12383515-B2 | Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver | MTI BIOTECH, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| EP-1539700-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | Prana Biotechnology Ltd (AU) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004087160-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS | PRANA BIOTECHNOLOGY LTD (AU) | 2004-10-14 | — | — | WO | disclosed |
| US-20040101521-A1 | Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression | THE BUCK INSTITUTE FOR RESEARCH ON AGING | 2004-05-27 | — | — | US | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004006856-A2 | IRON SEQUESTRATION OR ELIMINATION TO REDUCE NEURODEGENERATION OR PARKINSONS DISEASE PROGRESSION | THE BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102458-A1 | METHODS OF TREATING LONG TERM CORONAVIRUS INFECTION | ACE2, ACE, MICA | FFAR1 3352/4885FFAR4 3805/4885FAAH 3018/4885 |
| US-12383515-B2 | Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver | AKR7A2, CPT1A, FABP1 | FFAR1 242/4885FFAR4 586/4885FAAH 456/4885 |
| US-20250360094-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | CPT1A, AKR7A2, FABP1 | FFAR1 247/4885FFAR4 587/4885FAAH 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.